Poolbeg Pharma (LON:POLB) Shares Up 12.1% – Should You Buy?

Poolbeg Pharma PLC (LON:POLB)’s stock price shot up 12.1% during trading on Tuesday . The company traded as high as GBX 6.56 and last traded at GBX 6.56. 1,736,688 shares changed hands during trading, an increase of 36% from the average session volume of 1,280,718 shares. The stock had previously closed at GBX 5.85.

Analyst Ratings Changes

Separately, Shore Capital Group reiterated a “house stock” rating on shares of Poolbeg Pharma in a report on Tuesday, May 26th.

Poolbeg Pharma Price Performance

The firm has a market cap of £58.32 million, a price-to-earnings ratio of -8.80 and a beta of 1.78. The firm’s fifty day moving average is GBX 4.75 and its 200-day moving average is GBX 4.41.

Poolbeg Pharma (LON:POLB) last released its earnings results on Tuesday, April 28th. The company reported GBX (0.94) earnings per share (EPS) for the quarter. As a group, equities research analysts anticipate that Poolbeg Pharma PLC will post -0.68 EPS for the current year.

About Poolbeg Pharma

Poolbeg Pharma plc (AIM: POLB) is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company’s lead asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). As such, POLB 001 could increase the number of patients that can receive these life-saving treatments, thereby increasing the market opportunity.